BioCryst Pharmaceuticals Inc (BCRX) is a publicly traded Healthcare sector company. As of May 21, 2026, BCRX trades at $8.80 with a market cap of $2.28B and a P/E ratio of -5.07. BCRX moved -0.34% today. Year to date, BCRX is +17.95%; over the trailing twelve months it is -15.39%. Its 52-week range spans $6.00 to $11.31. Analyst consensus is strong buy with an average price target of $22.43. Rallies surfaces BCRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for BCRX combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $8.80 |
| Market Cap | $2.28B |
| P/E Ratio | -5.07 |
| EPS | $-1.73 |
| Dividend Yield | 0.00% |
| 52-Week High | $11.31 |
| 52-Week Low | $6.00 |
| Volume | 205 |
| Avg Volume | 0 |
| Revenue (TTM) | $885.72M |
| Net Income | $-457.98M |
| Gross Margin | 97.75% |
8 analysts cover BCRX: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $22.43.